Fluoroquinolone Resistance in Bacterial Isolates from Ocular Infections: Trend in Antibiotic Susceptibility Patterns Between 2005-2020

Overview

Journal Indian J Ophthalmol

Specialty Ophthalmology

Date 2022 Dec 1

PMID 36453351

Authors

Samrat Chatterjee

Deepshikha Agrawal

Sharad N Gomase

Swapnil M Parchand

Anil B Gangwe

Mihir Mishra

Affiliations

Soon will be listed here.

Abstract

Purpose: To assess the fluoroquinolone resistance pattern and trends among bacterial isolates from ocular infections over a 16-year period and explore alternative antibiotics in fluoroquinolone-resistant strains.

Methods: In this retrospective, longitudinal study, the microbiology laboratory records of patients with different ocular infections diagnosed at an eye institute in central India from 2005-2020 were reviewed to determine the pattern of fluoroquinolone (ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin) resistance. Antibiotic susceptibility testing was done using the Kirby-Bauer disc diffusion method.

Results: In 725 Gram-positive bacteria, the resistance of ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin was 55.9% (95% confidence interval [CI]: 52.2 - 59.6), 42.7% (95% CI: 39.0 - 46.4), 47.6% (95% CI: 43.9 - 51.3), and 45.6% (95% CI: 41.7-49.5), respectively. In 266 Gram-negative bacteria, the resistance of ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin was 57.9% (95% CI: 51.9 - 63.9), 56.0% (95% CI: 49.7 - 62.1), 59.9% (95% CI: 53.8 - 66.0), and 74.3% (95% CI: 68.3 - 80.2), respectively. A declining trend in resistance to ciprofloxacin (P < 0.001), ofloxacin (P < 0.001), and moxifloxacin (P < 0.001) was seen in Gram-positive bacteria, whereas a reduction in resistance to only moxifloxacin (P = 0.04) was seen in Gram-negative bacteria. In fluoroquinolone-resistant Gram-positive bacteria, cefuroxime exhibited the highest susceptibility, whereas in fluoroquinolone-resistant Gram-negative bacteria, colistin exhibited the highest susceptibility.

Conclusion: Fluoroquinolone resistance was high among bacteria from ocular infections in central India, but a declining trend in resistance to some of the fluoroquinolones was observed in recent times. Cefuroxime and colistin emerged as alternatives in fluoroquinolone-resistant Gram-positive and Gram-negative bacterial infections, respectively.

Citing Articles

Predisposing factors, clinical and microbiological insights of bacterial keratitis: analysis of 354 cases from a leading French academic centre.

Bertret C, Knoeri J, Leveziel L, Bourcier T, Brignole-Baudouin F, Merabet L Br J Ophthalmol. 2024; 109(1):15-20.

PMID: 38925906 PMC: 11671971. DOI: 10.1136/bjo-2024-325261.

Susceptibility of Ocular Surface Bacteria to Various Antibiotic Agents in a Romanian Ophthalmology Clinic.

Ghita A, Iliescu D, Ghita A, Ilie L Diagnostics (Basel). 2023; 13(22).

PMID: 37998545 PMC: 10670825. DOI: 10.3390/diagnostics13223409.

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach.

Al Hagbani T, Danish Rizvi S, Shakil S, Lila A Nanomaterials (Basel). 2023; 13(14).

PMID: 37513094 PMC: 10384196. DOI: 10.3390/nano13142083.

Microbiological spectrum and antibiotic susceptibility patterns of non-viral conjunctivitis over 16 years at a tertiary eye care center in Southern India.

Maiti S, Gandhi J, Joseph J Int Ophthalmol. 2023; 43(10):3717-3724.

PMID: 37395904 DOI: 10.1007/s10792-023-02781-4.

Therapeutic potential of phage lysin PlyB in ocular infections.

Mursalin M, Astley R, Coburn P, Bagaruka E, Hunt J, Fischetti V mSphere. 2023; 8(4):e0004423.

PMID: 37273201 PMC: 10449515. DOI: 10.1128/msphere.00044-23.

References

Kunimoto D, Sharma S, Garg P, Rao G . In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin. Emerging resistance. Ophthalmology. 1999; 106(1):80-5. DOI: 10.1016/S0161-6420(99)90008-8. View

Thomas R, Melton R, Vollmer P, Asbell P . In Vitro Antibiotic Resistance among Bacteria from the Cornea in the Antibiotic Resistance Monitoring in Ocular MicRoorganisms Surveillance Study. Optom Vis Sci. 2021; 98(9):1113-1121. PMC: 8505161. DOI: 10.1097/OPX.0000000000001768. View

Asbell P, Mah F, Sanfilippo C, DeCory H . Antibiotic susceptibility of bacterial pathogens isolated from the aqueous and vitreous humor in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. J Cataract Refract Surg. 2016; 42(12):1841-1843. DOI: 10.1016/j.jcrs.2016.11.008. View

Alexandrakis G, Alfonso E, Miller D . Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000; 107(8):1497-502. DOI: 10.1016/s0161-6420(00)00179-2. View

Chang V, Dhaliwal D, Raju L, Kowalski R . Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review. Cornea. 2015; 34(6):698-703. PMC: 4426026. DOI: 10.1097/ICO.0000000000000431. View

Das S, Samantaray R, Mallick A, Sahu S, Sharma S . Types of organisms and susceptibility of bacterial isolates from patients with microbial keratitis: A trend analysis of 8 years. Indian J Ophthalmol. 2018; 67(1):49-53. PMC: 6324162. DOI: 10.4103/ijo.IJO_500_18. View

Jorgensen J, Ferraro M . Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis. 2009; 49(11):1749-55. DOI: 10.1086/647952. View

Chatterjee S, Agrawal D . Multi-drug resistant Pseudomonas aeruginosa keratitis and its effective treatment with topical colistimethate. Indian J Ophthalmol. 2016; 64(2):153-7. PMC: 4850814. DOI: 10.4103/0301-4738.179721. View

Egrilmez S, Yildirim-Theveny S . Treatment-Resistant Bacterial Keratitis: Challenges and Solutions. Clin Ophthalmol. 2020; 14:287-297. PMC: 6996220. DOI: 10.2147/OPTH.S181997. View

10.

Garg P, Sharma S, Rao G . Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 1999; 106(7):1319-23. DOI: 10.1016/S0161-6420(99)00717-4. View

11.

Wang N, Yang Q, Tan Y, Lin L, Huang Q, Wu K . Bacterial Spectrum and Antibiotic Resistance Patterns of Ocular Infection: Differences between External and Intraocular Diseases. J Ophthalmol. 2015; 2015:813979. PMC: 4631901. DOI: 10.1155/2015/813979. View

12.

Asbell P, Sanfilippo C, Sahm D, DeCory H . Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018. JAMA Ophthalmol. 2020; 138(5):439-450. PMC: 7146550. DOI: 10.1001/jamaophthalmol.2020.0155. View

13.

Chawla B, Agarwal P, Tandon R, Titiyal J, Sharma N, Agarwal T . In vitro susceptibility of bacterial keratitis isolates to fourth-generation fluoroquinolones. Eur J Ophthalmol. 2009; 20(2):300-5. DOI: 10.1177/112067211002000207. View

14.

Asbell P, Sanfilippo C, Pillar C, DeCory H, Sahm D, Morris T . Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study. JAMA Ophthalmol. 2015; 133(12):1445-54. DOI: 10.1001/jamaophthalmol.2015.3888. View

15.

Nithya V, Rathinam S, Siva Ganesa Karthikeyan R, Lalitha P . A ten year study of prevalence, antimicrobial susceptibility pattern, and genotypic characterization of Methicillin resistant Staphylococcus aureus causing ocular infections in a tertiary eye care hospital in South India. Infect Genet Evol. 2019; 69:203-210. DOI: 10.1016/j.meegid.2019.01.031. View

16.

Lalitha P, Manoharan G, Karpagam R, Prajna N, Srinivasan M, Mascarenhas J . Trends in antibiotic resistance in bacterial keratitis isolates from South India. Br J Ophthalmol. 2016; 101(2):108-113. PMC: 7325411. DOI: 10.1136/bjophthalmol-2016-308487. View

17.

Acharya M, Farooqui J, Singh A, Gandhi A, Mathur U . Bacterial isolates in microbial keratitis: Three-year trend analysis from North India. Indian J Ophthalmol. 2019; 67(9):1508-1509. PMC: 6727695. DOI: 10.4103/ijo.IJO_678_19. View

18.

Goldstein M, Kowalski R, Gordon Y . Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999; 106(7):1313-8. View

19.

Acar J, Goldstein F . Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 1997; 24 Suppl 1:S67-73. DOI: 10.1093/clinids/24.supplement_1.s67. View

20.

De Oliveira D, Forde B, Kidd T, Harris P, Schembri M, Beatson S . Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev. 2020; 33(3). PMC: 7227449. DOI: 10.1128/CMR.00181-19. View